InvestorsHub Logo
Followers 825
Posts 119410
Boards Moderated 16
Alias Born 09/05/2002

Re: JK2016 post# 2197

Tuesday, 04/19/2022 9:46:01 AM

Tuesday, April 19, 2022 9:46:01 AM

Post# of 2919
Ascletis’ ASC11 could be a serious competitor to EDP-235 based on the in vitro assays of potency described in the PR (https://finance.yahoo.com/news/ascletis-announces-3clpro-inhibitor-asc11-085000053.html ). However, the most consequential differentiators among agents from this drug class are safety and pharmacokinetics, and Ascletis’ PR is silent on these points. We’ll have to wait for Ascletis’ phase-1 data in late 2022 (or early 2023) to know how their drug actually stacks up.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News